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Background: This phase 1 clinical trial was conducted to determine the safety, maximum-tolerated dose (MTD), and
pharmacokinetics of imatinib, bevacizumab, and metronomic cyclophosphamide in patients with advanced colorectal cancer (CRC).
Methods: Patients with refractory stage IV CRC were treated with bevacizumab 5mgkg 1 i.v. every 2 weeks (fixed dose) plus oral
cyclophosphamide q.d. and imatinib q.d. or b.i.d. in 28-day cycles with 3þ 3 dose escalation. Response was assessed every two cycles.
Pharmacokinetics of imatinib and cyclophosphamide and circulating tumour, endothelial, and immune cell subsets were measured.
Results: Thirty-five patients were enrolled. Maximum-tolerated doses were cyclophosphamide 50mg q.d., imatinib 400mg q.d.,
and bevacizumab 5mgkg 1 i.v. every 2 weeks. Dose-limiting toxicities (DLTs) included nausea/vomiting, neutropaenia,
hyponatraemia, fistula, and haematuria. The DLT window required expansion to 42 days (1.5 cycles) to capture delayed toxicities.
Imatinib exposure increased insignificantly after adding cyclophosphamide. Seven patients (20%) experienced stable disease for
46 months. Circulating tumour, endothelial, or immune cells were not associated with progression-free survival.
Conclusion: The combination of metronomic cyclophosphamide, imatinib, and bevacizumab is safe and tolerable without
significant drug interactions. A subset of patients experienced prolonged stable disease independent of dose level.
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Colorectal cancer (CRC) is the second leading cause of cancer
death in the United States (Jemal et al, 2010). Despite significant
improvements in treatment options over the past decade, the
median survival of patients with metastatic disease remains o2
years. Primary refractory disease, chemoresistance, and toxicity
leave many fit patients without a standard treatment option at
some point in their disease. New targets, treatments, and strategies
in advanced CRC are urgently needed.
Fundamental to tumour progression, angiogenesis was validated
as a therapeutic target in CRC with the demonstration that
bevacizumab, a monoclonal antibody against the vascular
endothelial growth factor (VEGF), increases response rate, delays
progression, and prolongs survival when combined with standard
chemotherapy (Folkman, 1971; Hurwitz et al, 2004). The
continuation of bevacizumab in second-line therapy after progres-
sion also improves survival (Grothey et al, 2008; Bennouna et al,
2013). Other agents with anti-angiogenic activity show benefit after
progression on bevacizumab-containing therapy, including rego-
rafenib, a multikinase inhibitor that targets VEGF receptor
signalling, and the novel decoy receptor fusion protein, aflibercept
(VEGF-Trap) (Van Cutsem et al, 2012; Grothey et al, 2013). The
precise mechanisms of action of bevacizumab, regorafenib, and
aflibercept are poorly understood. In addition to impairing tumour
angiogenesis, blockade of tumour-derived VEGF may modulate the
host immune response against tumours by increasing the
abundance of effector T cells and activated dendritic cells among
tumour infiltrating immune cells. Conflicting evidence exists,
however, with recent reports suggesting that VEGF inhibition may
result in decreased anti-tumour immunity by blocking VEGF-
mediated innate immune cell recruitment to the tumour (Li et al,
2006; Doloff and Waxman, 2012).
A different strategy to target tumour vasculature is the
‘metronomic’ administration of low-dose cytotoxic chemotherapy
continuously over time, without scheduled breaks (Kerbel and
Kamen, 2004). Metronomic chemotherapy is thought to
preferentially target proliferating tumour-associated endothelial
cells, impairing tumour angiogenesis and increasing apoptosis
in vitro and in animal models (Bocci et al, 2002; Bertolini et al,
2003). Models of metronomic administration of cytotoxic agents
suggest lower rates of toxicity and chemoresistance (Browder
et al, 2000; Bertolini et al, 2003; Emmenegger et al, 2004).
In patients with CRC, metronomic administration of irinotecan
was well tolerated and associated with disease stabilisation in a
subset of patients who previously had progressed on standard
schedules of irinotecan (Allegrini et al, 2008). Cyclophosphamide
is the cytotoxic agent most widely studied across metronomic
chemotherapy regimens (Penel et al, 2011). In addition to an
anti-angiogenic effect on tumour vasculature, metronomic
cyclophosphamide also may act by depleting CD4þ CD25þ
regulatory T cells (Tregs), thereby reducing their suppressive
effects on anti-tumour immune responses (Motoyoshi et al,
2006; Ghiringhelli et al, 2007; Penel et al, 2011). In a series of
12 patients with metastatic breast cancer treated with metronomic
cyclophosphamide, there was a transient significant reduction in
Tregs, associated with a sustained increase in breast tumour-
reactive T cells (Ge et al, 2012).
The addition of anti-angiogenic agents to metronomic cyclo-
phosphamide is synergistic in preclinical studies (Browder et al,
2000; Pietras and Hanahan, 2005; Blansfield et al, 2008; Penel et al,
2011). In a transgenic mouse model of pancreatic islet cell
tumours, Pietras and Hanahan (2005) showed that the combina-
tion of metronomic cyclophosphamide combined with the
multikinase inhibitors, imatinib and sunitinib, induced greater
anti-tumour activity than any of the three agents alone or pairwise.
Pericyte coverage of tumour blood vessels was reduced with the
combination, leading to the hypothesis that inhibition of
platelet-derived growth factor receptor-b (PDGFRb)-mediated
pericyte support may disrupt existing tumour vasculature and
augment anti-angiogenic effects. Blansfield et al (2008) studied a
combination of metronomic cyclophosphamide, lenalidomide
(an immunomodulatory and anti-angiogenic agent), and sunitinib
to target the tumour microenvironment in a xenograft model of
colon cancer. The combination of all three agents showed
significantly greater inhibition of tumour proliferation and
angiogenesis, and increased apoptosis, compared with any of
the agents alone.
Human studies of metronomic cyclophosphamide combined
with anti-angiogenic agents have demonstrated clinical evidence
of anti-tumour efficacy, although interpretation of these studies
is generally limited by small sample sizes, lack of a control arm,
and heterogeneity of tumour type, treatments, and end points
(Penel et al, 2011). A phase 2 trial of 70 patients with recurrent
ovarian cancer treated with the combination of bevacizumab plus
metronomic cyclophosphamide showed a promising 6-month
progression-free survival (PFS) of 56% and partial response rate
of 24% (Garcia et al, 2008). Another study in 38 patients with
refractory ovarian cancer showed a median PFS of 4.5 months
but was notable for grade 3 and 4 events of intestinal fistula,
hypertension, haematuria, and arterial thrombosis (Sanchez-
Munoz et al, 2010). In a study of 46 patients with advanced
breast cancer treated with metronomic cyclophosphamide and
capecitabine along with bevacizumab, an overall response
rate of 48% was observed with minimal toxicity (Dellapasqua
et al, 2008).
Building upon the preclinical rationale for combining metro-
nomic chemotherapy with an anti-VEGF agent plus a PDGFRb
antagonist (to inhibit pericyte-mediated endothelial cell survival
cues), we conducted a phase 1 trial to determine the safety,
tolerability, maximum-tolerated dose (MTD), and recommended
phase 2 dose (RP2D) of the combination of metronomic
cyclophosphamide, imatinib, and bevacizumab in patients with
advanced solid tumours for which bevacizumab is an approved
therapy. Because of the established role for bevacizumab in
metastatic CRC, the study was conducted in a CRC cohort.
Pharmacokinetic (PK) analyses and exploratory biomarker mea-
surements were performed.
PATIENTS AND METHODS
Patient selection. Patients were recruited and treated at the
University of California, San Francisco (UCSF) Helen Diller Family
Comprehensive Cancer Center. Patients with metastatic, histolo-
gically confirmed, incurable solid tumours refractory to standard
therapies or for which no standard therapy exists and the following
characteristics were eligible: age X18 years; Eastern Cooperative
Oncology Group (ECOG) performance status 0 or 1; insurance
approval for treatment with bevacizumab; measurable disease by
Response Evaluation Criteria in Solid Tumours (RECIST 1.0) with
evidence of progression clinically or radiographically at time of
enrollment; X4 weeks since completion of prior treatments;
resolution of any prior toxicity to pgrade 1 by National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0; adequate organ function. Patients with
uncontrolled hypertension or cardiovascular disease, arterial
thrombotic events within 12 months, central or cavitary lung
tumours in proximity to a major vessel, haemoptysis, abdominal
fistula, perforation, abscess, known brain metastasis, serious non-
healing wounds or fractures, or other significant comorbidities
were excluded. Prior therapy with bevacizumab was permitted.
Concomitant medications were reviewed and adjusted as needed to
avoid interactions. The trial was approved by the UCSF
Institutional Review Board and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice.
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Study design and endpoints. The study was an investigator-
initiated, open-label, single-arm, phase 1 clinical trial employing a
standard 3þ 3 dose-escalation design with a cycle length of 28
days. The primary end points were the safety and MTD of the
combination of imatinib, metronomic cyclophosphamide, and
bevacizumab in patients with advanced solid tumours. Secondary
end points were the effects of cyclophosphamide on imatinib PK
after single doses and at steady state, as well as response rate and
PFS. Exploratory end points included enumeration of circulating
tumour, endothelial, and immune cells at baseline, during therapy,
and at study termination.
Treatment plan. The starting dose of cyclophosphamide was
25mg orally once daily, with escalation to a target dose of 50mg
(Penel et al, 2011). Imatinib dosing started at 400mg daily, with
escalation to a target dose of 400mg orally twice daily based upon
evidence of dose-dependent efficacy in other diseases (Talpaz et al,
2002; Verweij et al, 2004; Zalcberg et al, 2005). For all dose levels
(DLs), a standard i.v. dose of 5mg kg 1 bevacizumab every other
week was employed (Hurwitz et al, 2004), see Table 2. Patients
were enrolled following a standard 3þ 3 dose escalation protocol,
starting at DL 0. If one dose-limiting toxicity (DLT) occurred
among the first three patients, then the cohort was expanded to six
patients. If 0 out of 3 or 1 out of 6 patients experienced a DLT, then
dose escalation proceeded with enrollment of three patients to the
next DL. The maximum DL with no more than one DLT in at least
six patients during the DLT window was designated as the MTD
and the RP2D. After identification of the MTD, an expansion
cohort of six patients was enrolled for PK. Intrapatient dose
escalation was not permitted. Imatinib was supplied by Novartis
Oncology. Bevacizumab and cyclophosphamide were obtained
from commercial supplies. Dose modifications for toxicity were
conducted individually for each drug according to attribution.
Supportive care including anti-diarrheal medications, anti-emetic
agents, management of hypertension, diuretics for oedema, and
topical therapies was administered as needed. Treatment was
continued until radiographic or clinical progression, unacceptable
toxicity, or withdrawal of consent. Patients removed from study for
symptomatic progression during the DLT window were replaced.
Assessment of safety and toxicity. Patients were assessed for
adverse events (AEs) weekly during cycle 1 and every 2 weeks in
subsequent cycles. AEs were characterised using NCI CTCAE
version 3.0. Laboratory abnormalities were reported as AE if
considered clinically significant by the treating investigator.
At study initiation, the DLT window was 1 cycle (28 days). After
21 patients had been accrued, the DLT window was expanded to 42
days (1.5 cycles), based upon the mid-study observation that many
patients required dose reduction for toxicity early in cycle 2, as
discussed below. The DLT definition included: grade 4 haemato-
logic toxicity except for grade 4 neutropaenia without fever lasting
o7 days; prolonged grade 3 thrombocytopaenia X7 days; any
grade X3 non-haematologic toxicity despite optimal supportive
care, excluding fatigue; any grade X2 toxicity requiring dose
modification or treatment delay42 weeks during DLT window; or
discontinuation of any of the study drugs due to toxicity.
Measurement of tumour response and PFS. Target and non-
target lesions were defined by RECIST version 1.0 (Therasse et al,
2000). Computerised tomography (CT) or magnetic resonance
imaging (MRI) of target and non-target lesions was performed at
baseline and after every two cycles (8 weeks±7 days) on protocol
therapy. PFS was calculated from the first dose of protocol therapy
until date of removal from study for radiographic or clinical
progression or death from any cause. Among patients who were
removed from study for reasons other than progression or death,
PFS was censored at date of last contact or study removal.
PK analysis of imatinib and cyclophosphamide. Bevacizumab
was assumed not to interact with the other agents. Pharmacoki-
netics of imatinib and cyclophosphamide was performed in an
expansion cohort of six patients at the MTD. Blood samples for
imatinib PK were collected in heparinised tubes over 24 h during
day 1 of cycle 1 (imatinib alone) and cycle 2 (at steady state for all
drugs). Samples times were before treatment, and at 0.5, 1, 2, 3, 4,
8, and 24 h after the cycle 1 day 1 (C1D1) dose; and at the same
times around the cycle 2 day 1 (C2D1) imatinib dose. Plasma was
prepared by centrifugation and immediately frozen at  20 1C.
Plasma concentrations of imatinib and its active metabolite,
CGP74588, were determined with a validated liquid chromato-
graphy-mass spectrometry (LC-MS) assay (Parise et al, 2003).
Plasma PK parameters, including area under the concentration vs
time curve (AUC) of imatinib and its metabolite were extracted
from the data by non-compartmental methods with PK Solutions
2.0 (Summit Research Services, Montrose, CO, USA). To assess any
effect of bevacizumab and cyclophosphamide on imatinib
pharmacokinetics, we compared the AUC0-inf on C1D1 with the
AUC0–24 h on C2D1.
For cyclophosphamide PK, 5ml of whole venous blood was
collected in an EDTA Vacutainer tube before cyclophosphamide
treatment and at 0.5, 1, 2, 3, 4, 8, and 24 h after cyclophosphamide
ingestion on C2D1. The blood samples were centrifuged at 4 1C at
2000 r.p.m. for 10min. Plasma samples were collected and frozen
at  80 1C until analysis. Cyclophosphamide concentration was
measured by LC-MS/MS) (Stempak et al, 2006). Estimates of PK
parameters for cyclophosphamide, including AUC, Cmax, Tmax, t1/2,
the apparent oral clearance (Cl/F) and apparent oral volume of
distribution (Vd/F) were derived from individual concentration-
time data sets by non-compartmental methods using the software
package WinNonlin (version 5.3, Pharsight Corporation, St Louis,
MO, USA).
Circulating tumour cell and circulating endothelial cell enu-
meration. Peripheral blood for circulating tumour cell (CTC)/
circulating endothelial cell (CEC) enumeration was obtained before
the start of therapy (baseline), at weeks 2, 6, and 8, and at end of
treatment. The number of CTCs in 7.5ml of blood was measured
using the CellSearch system (Veridex LLC, Raritan, NJ, USA)
(Cohen et al, 2008). Circulating tumour cells were defined as
nucleated EpCAM-positive cells that stain positive for cytokeratin
and negative for leukocyte common antigen, CD45 (Allard et al,
2004). Circulating endothelial cell was evaluated using a previously
described flow cytometry assay (Garcia et al, 2007; Rugo et al,
2012). It was identified by 4-colour flow cytometry using an
FACSCalibur Flow cytometer (BD Biosciences, San Jose, CA,
USA). It was defined as nucleated, CD31 positive, CD34 positive,
and CD45 negative. In addition, CEC-related subpopulations were
also evaluated including CD146-positive cells and progenitor and
activated CEC defined as CD133 positive and CD105 positive,
respectively.
The CTC and CEC values at baseline and on treatment were
explored for association with PFS and best response. Circulating
tumour cell was tested for correlation at each time point using
Spearman’s test. Cox proportional hazard models were used for
correlation with PFS. In the PFS models, CTC values were
dichotomised into (0, 1) variables using the accepted cutoff of X3
CTC/7.5ml (Cohen et al, 2008). The CEC data were modelled
using cell counts as continuous variables (log scale). Additional
PFS models evaluated change from baseline for CTC and CEC as a
dichotomous variable defined as increase or no increase at each
time point.
Immune cells. In a subset of six patients enrolled before
September 2008, peripheral blood mononuclear cells (PBMCs)
were isolated from blood samples by Ficoll gradient separation.
PBMC was cryopreserved at baseline and subsequent time points
Metronomic chemotherapy in colorectal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.553 1727
and assayed in parallel for each study subject. For phenotypic
characterisation, cells were thawed and stained with antibodies to
delineate CD4 and CD8 T cells. Tregs were identified by
intracellular FoxP3 staining and enumerated by flow cytometry.
Statistical analysis. Safety and toxicity were assessed by clinical
review of all relevant parameters including AEs, laboratory results,
vital signs, and other clinical measurements. The AE toxicities were
summarised by DL for all patients and by body system and grade.
The adverse experiences were summarised as counts, frequencies,
and grade at each DL. Descriptive statistics were used for safety,
tumour responses, PK, and other biomarker measurements.
Between-day PK comparisons were performed with a two-tailed,
Wilcoxon exact signed rank test, where Po0.05 was considered as
significant. For efficacy assessment, response rate (stable disease or
progressive disease) was estimated as counts and proportion. PFS
was analysed using Kaplan–Meir methods to estimate the mean
and median with 95% confidence interval and descriptively
summarised as appropriate by DL and by overall patients. Due
to the cohort sample size, no formal statistical testing was
performed for the safety or response results.
RESULTS
Patient characteristics. A total of 35 patients, all with a diagnosis
of metastatic CRC, were enrolled on this study between August
2006 and June 2010. Baseline characteristics of the patients are
shown in Table 1. The study population was heavily treated with a
median of three prior lines of therapy, and all patients (100%) had
failed prior 5-fluorouracil and/or capecitabine, oxaliplatin, irino-
tecan, and bevacizumab. Twenty-four of thirty-five (69%) had
received a monoclonal antibody targeting the epidermal growth
factor receptor (EGFR). Tumour K-ras gene was mutant in
9 (26%), wild type in 3 (9%), and unknown in 23 (66%), due to the
fact that this study was initiated before the establishment of K-ras
mutation as a biomarker for non-response to EGFR-targeted
therapies in CRC. Accrual by DL is shown in Table 2.
Dose escalation, DLT, and MTD. DLTs were observed in all four
DLs (Table 2). Initially designed with a DLT window of 28 days
(1 cycle), 1 of 6 patients had a DLT of possibly related, grade
2 gastrointestinal fistula development at DL0, followed by 0 of
3 patients with DLT in both DL þ 1 and þ 2. Three patients were
subsequently enrolled to DLþ 3. One patient was non-evaluable
due to disease progression and was replaced. One patient had a
DLT of grade 2 vomiting along with grade 3 hyponatraemia
requiring dose reduction during the DLT window. This led to
cohort expansion by three additional patients plus one replacement
patient, without any DLTs. Two more patients then enrolled to
DLþ 3 into the planned 6-patient PK expansion cohort. At that
point, it was noted that five of the nine patients enrolled to DLþ 3
required dose reductions early in cycle 2 due to toxicity occurring
shortly after the protocol-defined DLT window. Given concerns
regarding poor tolerability with chronic therapy, the protocol was
amended to expand the DLT window to 42 days (1.5 cycles). Under
the revised DLT window, five of nine patients at DLþ 3 and one of
three patients previously treated at DLþ 2 were re-adjudicated as
having had DLT events, so dosing was de-escalated to DLþ 2. One
of the two additional patients enrolled to DLþ 2 experienced a
DLT of grade 2 vomiting on day 18, resulting in two of five patients
at this DL with DLT and requiring de-escalation to DLþ 1. The
DLþ 1 was expanded by four additional patients (as one of three
original patients in this cohort had been removed for disease
progression at 34 days, and thus was not evaluable for toxicity
within the expanded 42-day DLT window). Among the six
evaluable patients enrolled to DLþ 1, one patient experienced a
DLT of grade 2 nausea despite optimal supportive care requiring
dose reduction during DLT window. The DLþ 1 was subsequently
determined to be the MTD and RP2D with one DLT occurring
among six evaluable patients.
Six additional patients were enrolled to the planned PK
expansion cohort at DLþ 1. Two of these patients were not
evaluable for PK and were replaced with two additional patients for
a total of eight patients in this cohort.
AEs and patient disposition. Table 3 displays treatment-related
AE. Overall, treatment-related AE was observed in 34 of 35 (97%)
of patients, with treatment-related gradeX3 AE occurring in 11 of
Table 1. Baseline patient demographics and clinical characteristics
Characteristic Median (range, N¼35)
Age 58 (33–74)
Number prior lines of therapy for
metastatic disease
3 (2–6)
Characteristic Number of patients (%, of N¼35)
Gender
Male 20 (57)
Female 15 (43)
Race/ethnicity
White 29 (83)
Black 2 (6)
Asian 2 (6)
Hispanic 0 (0)
Other 1 (3)
Unknown 1 (3)
Cancer location
Colon 24 (69)
Rectum 11 (31)
ECOG score
0 27 (77)
1 8 (23)
Prior systemic therapies
5-fluorouracil and/or capecitabine 35 (100)
Oxaliplatin 35 (100)
Irinotecan 35 (100)
Bevacizumab 35 (100)
Cetuximab and/or panitumumab 24 (69)
Investigational agent(s) 4 (11)
Prior radiation and/or surgery
Rectal irradiation 8 (23)
Metastatic site irradiation 3 (9)
Primary tumour resection 35 (100)
Metastatic site resection 15 (43)a
Liver-directed non-surgical therapyb 13 (37)a
KRAS mutational status
Wild type 3 (9)
Mutantc 9 (26)
Unknown 23 (66)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; KRAS = kirsten ras gene.
aPatients for whom multiple procedures of same type performed were counted only once.
bChemoembolisation (n¼ 1), ablative procedure (n¼ 8), and hepatic arterial infusion (n¼ 4).
cFor characteristic activating mutations.
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35 patients (31%). The most common treatment-related AEs (with
incidenceX20% in the overall population) were nausea, fatigue,
vomiting, diarrhoea, anorexia, rash, neutropaenia, hyperbilirubi-
naemia, and proteinuria. The majority of symptomatic toxicities
were amenable to supportive care including anti-emetic, anti-
diarrheal, and topical agents. Grade 3 and 4 events assessed as at
least possibly treatment related were neutropaenia (11%), hyperbi-
lirubinaemia (6%), hypertension (6%), hyponatraemia (6%),
abdominal pain (3%), erythaema multiforme (3%), haematuria
(3%), and pulmonary embolism (3%).
Among the 35 patients enrolled, 33 patients were removed from
study upon disease progression: 28 for radiographic progression,
3 for clinical progression, and 2 for death attributed to disease
progression on study. Only one patient required treatment
discontinuation for toxicity (possibly related grade 2 abdominal
fistula resulting in a DLT in DL0, followed by radiographic
progression within 1 month later). One grade 5 possibly-related
death occurred in DLþ 1 in a patient who developed intermittent
right upper quadrant, flank, and epigastric pain for which protocol
therapy was held on C7D1 and not restarted. One week later, he
was hospitalised for abdominal pain. The CT imaging was negative
for acute obstructive or thrombotic events, so he was discharged
after optimisation of pain medications. One week following this, he
collapsed after acute abdominal pain and bilious emesis. He was
found in cardiopulmonary arrest and expired in transit to hospital.
The cause of death was unknown.
Response to therapy and PFS. The best response was uncon-
firmed stable disease in 15 (43%) and confirmed stable disease in 7
(20%) of the 35 patients enrolled. The median PFS in the overall
study population was 1.88 months (95% confidence interval: 1.85,
3.60), with PFS ranging from 1.0 to 14.7 months. In all, 7 (20%) of
the 35 patients had stable disease for at least 6 months. Among
these patients, six of seven (86%) demonstrated evidence of
radiographic progression at study entry; the remaining patient had
clinical progression. There was no significant difference in PFS or
response across DLs (Figure 1).
Pharmacokinetics. Five of six planned patients enrolled at the
MTD expansion cohort were evaluable for cyclophosphamide and
imatinib pharmacokinetics. One patient was not evaluable due to
incomplete collection of PK samples. Imatinib pharmacokinetics
are presented in Table 4. Values for imatinib Cmax increased
between C1D1 and C2D1, as expected based on the drug’s long
half-life. Exposure values of imatinib and CGP74588 on C1D1
(AUC0-inf) and C2D1 (AUC0–24 h because imatinib is at steady
state) appeared to increase, but these effects did not reach statistical
significance (P¼ 0.063), as shown in Figures 2A and B and Table 4.
The mean cyclophosphamide plasma concentrations at each
time point are plotted against time in Supplementary Figure S1.
Cyclophosphamide PK parameters were calculated using the
plasma concentrations obtained during 24 h after treatment.
Cyclophosphamide treatment at a dose of 50mg resulted in a
Cmax of 1234±162 mg l
 1 at 0.8 h post dosing. AUC0-inf was
17588±4929 mg l 1 h), the elimination t1/2 was 10.8±2.2 h, the
Vd/F was 0.45±0.04 l kg 1 and the Cl/F of the drug was
0.03±0.01 l h 1 kg 1. The cyclophosphamide PK parameter data
are presented in Supplementary Table S1.
CTC and CEC. Circulating tumour cells in 7.5ml of blood were
enumerated using the CellSearch system (Janssen Diagnostics,
LLC, Raritan, NJ, USA). At baseline, 47% (15 out of 32) of
patients had unfavourable CTC levels (X3 CTC per 7.5ml
of blood) with a median of 1 CTC per 7.5ml (range 0–118).
Circulating tumour cell numbers at baseline and other time
points as well as changes in levels of CTCs during treatment did
not show statistically significant correlation with time to
treatment failure (TTF), PFS, or best response.
The CECs and CEC-related subpopulations were enumerated in
50 ml of blood by flow cytometry (Rugo et al, 2012). At baseline,
median CEC CD31þ and CEC CD146þ were 16.3 cells per ml
(range 3.2–44.5) and 1.1 cells per ml (range 0.1–10.2), respectively.
Baseline median progenitor (CD133þ ) and activated (CD105þ )
CEC were 0.48 cells per ml (range 0.02–27.17) and 4.37 cells per ml
(range 1.20–27.49), respectively. Absolute levels and change in
CEC and CEC subpopulations during treatment did not show any
correlation with outcome and response. However, the ratio of CEC
subpopulations CD146þ /CD31þ at cycle 1 day 15 showed a
significant correlation with TTF (P¼ 0.0007), PFS (P¼ 0.0002),
and best response (P¼o0.0001).
Immune cells. To assess whether this combination regimen
induced any immunomodulatory effects, blood samples obtained
every 2 weeks on study were assessed for the frequency and
activation status of T-cell and dendritic cell subsets. Two of six
assessed patients appeared to have an increase in the frequency of
Table 2. Dose levels, enrollment, and DLT in days 1–42
Dose level
Cyclophosphamide
(mg PO)
Imatinib
(mg PO)
Bevacizumab
(mgkg1 i.v.)
Actual Enrollment
(DLT, N) DLT (n)
 2 25 QOD 300 QD 5 days 1, 15 0 N/A
 1 25 QD 300 QD 5 days 1, 15 0 N/A
0a 25 QD 400 QD 5 days 1, 15 6 (1) Gr2 fistula (1)
þ 1 50 QD 400 QD 5 days 1, 15 15b (1) Gr2 vomiting (1)
þ 2 50 QD 300 BID 5 days 1, 15 5 (2) Gr2 vomiting, hyponatraemia (1)
Gr2 vomiting (1)
þ 3 50 QD 400 BID 5 days 1, 15 9 (5c) Gr4 neutrophils (1)
Gr2 nausea, Gr4 neutrophils (1)
Gr2 vomiting, Gr3 hyponatraemia (1)
Gr2 nausea (1)
Gr2 haematuria (1)
Abbreviations: BID¼ twice daily; DLT¼dose-limiting toxicity; Gr¼grade by CTCAE v3.0; MTD¼maximum-tolerated dose; n¼ number of individual DLT; N/A¼not applicable; N¼ number of
total DLT; PO¼orally; PK¼pharmacokinetics; QD¼daily; QOD¼ every other day; RP2D¼ recommended phase 2 dose.
aStarting dose level.
bIncludes expansion by eight additional patients for PK once MTD and RP2D identified.
cRe-adjudicated after retrospective extension of DLT window to 1.5 cycles (42 days).
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FoxP3þ Treg cells, while there were no apparent changes
observed in four of six patients (Supplementary Figure S2). There
were no consistent changes in other subsets.
DISCUSSION
To our knowledge, this is the first published clinical trial studying
metronomic chemotherapy combined with anti-angiogenic agents
in a cohort of patients with refractory metastatic CRC. The results
of this phase 1 trial suggest that metronomic oral administration of
50mg cyclophosphamide daily combined with 400mg imatinib
orally daily and 5mg kg 1 i.v. bevacizumab every other week has
acceptable safety and tolerability in a heavily pre-treated patient
population. The most common treatment-related AEs in all
patients were nausea, fatigue, vomiting, and diarrhoea; these were
manageable with aggressive supportive care. Seven of thirty-five
patients (20%), among whom 86% had radiographic progression at
study enrollment, demonstrated disease stabilisation for at least 6
Table 3. Treatment-related adverse events by dose level
Dose level 0 (n¼6) Dose level þ1 (n¼15) Dose level þ2 (n¼5) Dose level þ3 (n¼9)
Body system Overall All grades Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Blood
Haemoglobin 4 (11%) 1 (17%) 0 2 (13%) 0 0 0 1 (11%) 0
Neutrophils 8 (23%) 1 (17%) 0 2 (13%) 0 1 (20%) 1 (20%) 0 3 (33%)
Platelets 4 (11%) 0 0 2 (13%) 0 2 (40%) 0 0 0
Cardiac
Hypertension 6 (17%) 2 (33%) 0 0 2 (13%) 1 (20%) 0 1 (11%) 0
Constitutional
Fatigue 23 (66%) 0 0 12 (80%) 1 (7%) 2 (40%) 0 8 (89%) 0
Insomnia 5 (14%) 0 0 4 (27%) 0 0 0 1 (11%) 0
Death 1* (3%) 0 0 0 1a (7%) 0 0 0 0
Dermatologic
Rash 8 (23%) 3 (50%) 0 2 (13%) 0 2 (40%) 0 1 (11%) 0
Erythaema multiforme 1 (3%) 0 0 0 1 (7%) 0 0 0 0
Gastrointestinal
Nausea 26 (74%) 3 (50%) 0 10 (67%) 0 5 (100%) 0 8 (89%) 0
Diarrhoea 12 (34%) 2 (33%) 0 6 (40%) 0 1 (20%) 0 3 (33%) 0
Vomiting 17 (49%) 2 (33%) 0 6 (40%) 0 4 (80%) 0 5 (56%) 0
Anorexia 8 (23%) 0 0 7 (47%) 0 0 0 1 (11%) 0
Taste alteration 4 (11%) 0 0 0 0 1 (20%) 0 3 (33%) 0
Lymphatic
Oedema 5 (14%) 0 0 3 (20%) 0 0 0 2 (22%) 0
Metabolic
Proteinuria 7 (20%) 1 (17%) 0 5 (33%) 0 0 0 1 (11%) 0
Hyperbilirubinaemia 7 (20%) 0 0 5 (33%) 1 (13%) 0 0 0 1 (11%)
Creatinine increased 4 (11%) 0 0 2 (13%) 0 0 0 2 (22%) 0
Alkaline phos incr 2 (6%) 0 0 0 1 (7%) 0 0 1 (11%) 0
Hyponatraemia 2 (6%) 0 0 0 0 0 0 0 2 (22%)
Renal
Haematuria 1 (3%) 0 0 0 0 0 0 1 (11%)
Pain
Abdominal pain 2 (6%) 0 0 1 (7%) 1 (7%) 0 0 0 0
Pulmonary/Vascular
Thrombosis 1 (3%) 0 0 0 0 0 0 0 1 (11%)
Abbreviation: AEs¼ adverse events. AllXgrade 3 AEs assessed as at least possibly treatment related are reported. For grade 1 and 2 AEs, only those with overall incidence ofX11% (at least
four patients) are reported. For overlapping toxicities reported in the same patient (i.e., cystitis and urinary tract infection), only the highest grade and/or principal toxicity is reported.
aGrade 5 event.
BRITISH JOURNAL OF CANCER Metronomic chemotherapy in colorectal cancer
1730 www.bjcancer.com |DOI:10.1038/bjc.2013.553
PFS by dose level
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Figure 1. Progression-free survival and dose level. PFS was calculated from the first dose of protocol therapy until date of removal from
study for radiographic or clinical progression or death from any cause. Among patients who were removed from study for reasons other than
progression or death, PFS was censored at date of last contact or study removal. There was no significant difference in PFS or response across
dose levels.
Table 4. Pharmacokinetic parameters of imatinib and CGP74588
Subject
Weight
(kg)
Dose
(mg)
IMA
Cmax
(lgml 1)
C1D1
IMA
Cmax
(lgml 1)
C2D1
IMA
AUC0-inf
(lghml1)
C1D1
IMA
AUC0–24
(lghm 1l)
C2D1
CGP
Cmax
(lgml 1)
C1D1
CGP
Cmax
(lgml 1)
C2D1
CGP
AUC0-inf
(lghml 1)
C1D1
CGP
AUC0–24
(lghml 1)
C2D1
30 131 400 2.17 2.78 32.4 42.5 0.326 0.399 4.27 6.95
32 94 400 3.56 4.50 48.1 64.9 0.387 0.663 5.32 8.14
33 97 400 4.16 5.19 64.5 82.8 0.534 0.924 8.40 17.3
34 89 400 4.89 3.01 67.1 39.9 0.735 0.844 10.8 14.9
35 94 400 3.31 3.87 40.3 45.4 0.372 0.732 5.52 9.71
Mean 101 400 3.62 3.87 50.5 55.1 0.471 0.712 6.87 11.4
±s.d. ±17 ±1.01 ±1.01 ±15.1 ±18.4 ±0.167 ±0.202 ±2.69 ±4.5
P-value 0.63 P-value 0.63 P-value 0.063 P-value 0.063
Abbreviations: AUC0-inf¼ area under the plasma concentration-time curve from time zero to infinity; C1D1¼ cycle 1 day 1; C2D1¼ cycle 2 day 1; PK¼pharmacokinetics. Data are expressed as
mean±standard deviation. Between-day PK comparisons were performed with a two-tailed, Wilcoxon exact signed rank test, where Po0.05 was considered as significant.
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Figure 2. Pharmacokinetics of imatinib and CGP74588. Area under the concentration vs time curve on C1D1 (AUC0-inf) and C2D1 (AUC0–24h
because imatinib is at steady state) was compared for imatinib (A) and its metabolite, CGP74588 (B). Values for imatinib Cmax increased between
C1D1 and C2D1, as expected based on the drug’s long half-life. Exposure values of imatinib and CGP74588 on C1D1 and C2D1 appeared to
increase, but these effects did not reach statistical significance (P¼0.063).
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months, though there were no radiographic responses by RECIST
1.0, and the majority of patients progressed within 2 months.
Although the prolonged disease stability observed in 20% is
intriguing, the findings in our study provide an inadequate signal
to justify further study in the absence of predictive biomarkers and/
or a more complete understanding of mechanisms underlying the
potential anti-tumour efficacy. In this phase 1, single arm study,
the true anti-tumour activity of the regimen or its individual
components is impossible to gauge. Results from the TML trial are
relevant, as they suggest that bevacizumab itself has activity post
progression and raise the possibility that the events of disease
stabilisation observed in our study could be due to effects of
bevacizumab alone (Grothey et al, 2008; Bennouna et al, 2013).
Whether cyclophosphamide is the optimal cytotoxic agent for
metronomic dosing in CRC remains not known (recognising that
tumour-associated endothelial cells are at least one target).
Furthermore, other PDGFRb inhibitors have been developed since
the inception of this study, including regorafenib (whose targets
include VEGFR1, VEGFR2, VEGFR3, PDGFRb, Kit, RET, and Raf-1),
which is now approved for refractory CRC and has a distinct, but
overlapping profile of target inhibition compared with imatinib
(Grothey et al, 2013). Nonetheless, the safety data and pharma-
cokinetics in this novel study may inform future metronomic and
combination therapy approaches.
This study exemplifies the challenges of toxicity and tolerability
assessment and attribution in multi-drug targeted therapy regimens.
An important observation is that intolerability due to a constellation
of grade 1 and 2 AEs occurred in a significant proportion of patients,
resulting in delays and dose reductions soon after completion of the
standard 28-day (1 cycle) DLT window. In response to this finding,
the DLT window was expanded to 42 days (1.5 cycles), leading to
identification of significantly more toxicity than initially appreciated
and requiring de-escalation from DL þ 3 to DL þ 1, the eventual
MTD regimen (and RP2D). Similar to our experience, Postel-Vinay
et al (2011) recently described the toxicity among 445 patients treated
with molecularly targeted agents on phase 1 trials at the Royal
Marsden Hospital and Institut Gustave Roussy between January 2005
and July 2008. The authors found that 57% of grade 3 and 4
treatment-related toxicities occurred after cycle 1 of therapy and
concluded that toxicities from targeted therapies regularly occur
beyond the traditional DLT window and may be important in
determining the RP2D (Postel-Vinay et al, 2011).
Another important question raised is how to determine the
optimal biologic dose of combination targeted therapy regimens,
since the MTD identified by the standard model of dose escalation
may not be equivalent to the optimal biologic dose for every drug
or combination (Parulekar and Eisenhauer, 2004; Sleijfer and
Wiemer, 2008; Postel-Vinay et al, 2011). On-treatment biopsies to
test for target engagement or other pharmacodynamic markers are
desirable but not uniformly feasible across studies, particularly in
the setting of combination regimens for which a validated measure
of the complex interplay of multiple agents may not be available.
In this study, DCE-CT imaging was undertaken in a small subset of
patients to examine the hepatic tumour perfusion as a measure of
anti-angiogenic activity (Flaherty et al, 2008; Hahn et al, 2008;
Raatschen et al, 2009; Kummar et al, 2011; Ren et al, 2012). Among
the patients who underwent serial DCE-CT on this study, no
informative changes were observed in tumour blood volume, Ktrans,
permeability surface, mean transit time, or blood flow, though
interpretation of these results is limited by the small sample size
and the modest therapeutic efficacy (data not shown).
Imatinib C1D1 AUC0-inf and C2D1 AUC0–24h values observed
were in the range of 30–80 mg hml 1, which agrees with exposures
at doses of 400–600mg reported in the literature (Peng et al, 2005).
The increase in imatinib Cmax over serial time points could be
explained by the expected accumulation index based on the
imatinib half-life and the dose interval. The increases in imatinib
and CGP74588 AUC over serial time points suggest that addition
of bevacizumab and cyclophosphamide reduces imatinib clearance.
However, these effects did not reach statistical significance in this
small sample. Human CYP3A4 is involved in the metabolism of
cyclophosphamide, and could possibly be a competitive inhibitor
to imatinib metabolism (Bohnenstengel et al, 1996). On the other
hand, cyclophosphamide has been reported to induce CYP3A4
metabolism in human liver slices, potentially leading to increased
imatinib metabolism (Martin et al, 2003). The net effect in this trial
could be inhibition of imatinib metabolism, and this is supported
by a murine study showing a 41% reduction in CYP3A4 activity
after 8 weeks of cyclophosphamide treatment (Emmenegger et al,
2007).
Pharmacokinetic analyses showed that the exposure to 50mg
daily metronomic dosing of cyclophosphamide, measured on cycle
2, day 1 with imatinib at steady state, was consistent with previous
single dose cyclophosphamide PK data for adult non-Hodgkin’s
lymphoma and for paediatric recurrent solid tumours, suggesting
against a significant interaction with imatinib (Stempak et al,
2006). Technical difficulties precluded measurement of 4-hydro-
peroxycyclophosphamide (4-OHCP) levels, the major active
(cytotoxic) microsomal metabolite of cyclophosphamide.
Levels of CTCs (at baseline and changes on therapy) were not
associated with PFS or response in the study population. Though
multiple other studies and meta-analysis data have established
CTC as a poor prognostic factor and potential predictive marker of
early response, the majority of these studies examined patients
earlier in their disease history, particularly first-line metastatic
CRC (Cohen et al, 2009; Rahbari et al, 2010; Tol et al, 2010). We
surmise that the heavily pretreated patient population, modest
treatment efficacy, and small sample size may have obscured our
ability to detect any meaningful relationship in our study. The
significance of the association between the absolute number of
CD146-positive CECs on cycle 1, day 15 and outcome is unclear,
owing to the small sample size and the absence of any trend at
other time points (noting that a Bonferroni correction was not
performed).
While both metronomic cyclophosphamide and VEGF-targeted
therapy as single-agent treatments have been shown to enhance
anti-tumour immunity by reducing the frequency of Tregs or
enhancing dendritic cell activation (Li et al, 2006), our study
combining these approaches showed no apparent increase in
effector T cells, while Tregs appeared to increase on therapy in two
of the six patients assessed. Though interpretation is limited by
small sample size, this finding is reminiscent of a recent report
showing an unexpected decrease in innate immune cell recruit-
ment and decreased tumour regression when VEGF receptor
inhibition was added to metronomic cyclophosphamide in a mouse
model of brain tumours (Doloff and Waxman, 2012). These results
highlight the need for valid preclinical models and the importance
of integrating pharmacodynamic studies when undertaking novel
combinations in clinical trials.
The combination regimen of metronomic cyclophosphamide,
imatinib, and bevacizumab in heavily pretreated patients with
refractory metastatic CRC appears to be safe. Successful develop-
ment of this therapeutic strategy would require randomised trials
designed to determine the incremental benefit of each individual
component, ideally compared with a best supportive care arm in
the treatment-refractory setting. Given the refractory nature of this
patient population and the anticipated modest benefit in the group
as a whole, predictive biomarkers and improved tools to detect
response would significantly improve the ability to discern and
define benefit. Our data suggest that a standard 28-day DLT
window may not adequately capture tolerability of a metronomic
regimen, and that the activity of metronomic regimens may be best
measured by time-to-event end points such as PFS or time to
progression rather than response rate. Furthermore, while toxicity
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appears to be dose dependent, our data show no clear relationship
between dose and efficacy. Predictive biomarkers along with
pharmacodynamic markers of target engagement are needed to
understand the mechanisms of action, discern optimal biologic
dose, and identify the patients most likely to respond to a
metronomic approach, and to anti-angiogenic therapies in general.
The limited success to date to identify consistent predictive
biomarkers of response to bevacizumab across tumour types
underscores the complexity of angiogenesis and the tumour
microenvironment as therapeutic targets.
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